指南与共识腹部MR

2018 KLCA-NCC指南与LI-RADS v2018在钆塞酸增强MRI诊断HCC中的性能比较

Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
指南 / 共识 · Korean J Radiol · 2021-03-09

回顾性纳入387例慢性乙型肝炎或肝硬化患者的422个肝脏病变,比较2018 KLCA-NCC指南与LI-RADS v2018在钆塞酸增强MRI上诊断HCC的效能。在全部病变中,KLCA-NCC的definite HCC较LR-5敏感度更高但特异度更低;在≥2 cm病变中,definite HCC较LR-5敏感度更高且特异度无显著降低。definite/probable HCC与LR-5/4的敏感度和特异度无显著差异。

要点

  • 全部病变中,definite HCC敏感度87.2%高于LR-5的80.8%,特异度86.2%低于LR-5的91.0%。
  • ≥2 cm病变中,definite HCC敏感度86.8%高于LR-5的82.0%,特异度80.0% vs 83.3%无显著差异(p=0.15)。
  • definite/probable HCC与LR-5/4的敏感度(89.7% vs 91.5%)和特异度(83.5% vs 79.3%)无显著差异。

诊断标准与关键数值

  • 全部病变中,definite HCC(2018 KLCA-NCC指南)敏感度87.2%(204/234),特异度86.2%(162/188)。
  • 全部病变中,LR-5(LI-RADS v2018)敏感度80.8%(189/234),特异度91.0%(171/188)。
  • ≥2 cm病变中,definite HCC敏感度86.8%(164/189),特异度80.0%(48/60);LR-5敏感度82.0%(155/189),特异度83.3%(50/60)。
  • 全部病变中,definite/probable HCC敏感度89.7%(210/234),特异度83.5%(157/188);LR-5/4敏感度91.5%(214/234),特异度79.3%(149/188)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the performance of the 2018 Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) Practice Guidelines (hereafter, PG) for the diagnosis of hepatocellular carcinoma (HCC) using gadoxetic acid-enhanced MRI, compared to the Liver Imaging-Reporting and Data System (LI-RADS) version 2018 (hereafter, v2018).

MATERIALS AND METHODS: From January 2013 to October 2015, treatment-naïve hepatic lesions (≥ 1 cm) on gadoxetic acid-enhanced MRI in consecutive patients with chronic hepatitis B or cirrhosis were retrospectively evaluated. For each lesion, three radiologists independently analyzed the imaging features and classified the lesions into categories according to the 2018 KLCA-NCC PG and LI-RADS v2018. The imaging features and categories were determined by consensus. Generalized estimating equation (GEE) models were used to compare the per-lesion diagnostic performance of the 2018 KLCA-NCC PG and LI-RADS v2018 using the consensus data.

RESULTS: In total, 422 lesions (234 HCCs, 45 non-HCC malignancies, and 143 benign lesions) from 387 patients (79% male; mean age, 59 years) were included. In all lesions, the definite HCC (2018 KLCA-NCC PG) had a higher sensitivity and lower specificity than LR-5 (LI-RADS v2018) (87.2% [204/234] vs. 80.8% [189/234], p < 0.001; 86.2% [162/188] vs. 91.0% [171/188], p = 0.002). However, in lesions of size ≥ 2 cm, the definite HCC had a higher sensitivity than the LR-5 (86.8% [164/189] vs. 82.0 (155/189), p = 0.002) without a reduction in the specificity (80.0% [48/60] vs. 83.3% [50/60], p = 0.15). In all lesions, the sensitivity and specificity of the definite/probable HCC (2018 KLCA-NCC PG) and LR-5/4 did not differ significantly (89.7% [210/234] vs. 91.5% [214/234], p = 0.204; 83.5% [157/188] vs. 79.3% [149/188], p = 0.071).

CONCLUSION: For the diagnosis of HCC of size ≥ 2 cm, the definite HCC (2018 KLCA-NCC PG) had a higher sensitivity than LR-5, without a reduction in specificity. The definite/probable HCC (2018 KLCA-NCC PG) had a similar sensitivity and specificity to that those of the LR-5/4.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Lee SM, Lee JM, Ahn SJ, et al. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018. Korean J Radiol. 2021. PMID: 33739633. doi:10.3348/kjr.2020.0846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。